Viral vectors, especially adeno-associated virus (AAV), have emerged as promising tools for gene therapy. However, many obstacles remain in navigating a process from development through manufacturing. In this video, we'll explore how FlexFactory™ manufacturing platforms from Cytiva can help you overcome these challenges with a single-use solution ― designed with deep biomanufacturing expertise ― that’s integrated across your entire viral vector production workflow.
20 май 2024
